Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

Cathy Biga, ACC President
ACC News
Cathie Biga is New American College of Cardiology President
04/09/2024

American College of Cardiology News

American College of Cardiology News ...
Cathie Biga, MSN, FACC, has became president of the American College of Cardiology as of April 8, 2024, and made history as the organization’s first non-physician president. She will serve a one-year term representing over 56,000...
Cathie Biga, MSN, FACC, has became president of the American College of Cardiology as of April 8, 2024, and made history as the organization’s first non-physician president. She will serve a one-year term representing over 56,000...
Cathie Biga, MSN, FACC, has...
04/09/2024
Cath Lab Digest
Beta Blockers Post MI
ACC.24: REDUCE-AMI - Beta Blockers May Not Benefit Many Heart Attack Survivors
04/09/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
“I think that, following this study, many doctors will not find an indication to routinely treat all their patients with beta blockers following a heart attack,” said Troels Yndigegn, MD, interventional cardiologist at Lund University in...
“I think that, following this study, many doctors will not find an indication to routinely treat all their patients with beta blockers following a heart attack,” said Troels Yndigegn, MD, interventional cardiologist at Lund University in...
“I think that, following this...
04/09/2024
Cath Lab Digest

Advertisement

Vulnerable plaque
ACC.24: PREVENT Trial - Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events
04/09/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
The trial findings suggest that people with high-risk plaques that are likely to rupture could benefit from PCI as a preemptive measure rather than waiting for a heart attack or other severe reduction in blood flow to occur. The PREVENT trial...
The trial findings suggest that people with high-risk plaques that are likely to rupture could benefit from PCI as a preemptive measure rather than waiting for a heart attack or other severe reduction in blood flow to occur. The PREVENT trial...
The trial findings suggest that...
04/09/2024
Cath Lab Digest
Hypertension
ACC.24: Trial Reports Mixed Results with Nerve Ablation for High Blood Pressure
04/09/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
“We saw a modest but statistically significant difference in the primary endpoint, but there were no significant differences in other measures of blood pressure, including office systolic or diastolic blood pressure,” said David E. Kandzari,...
“We saw a modest but statistically significant difference in the primary endpoint, but there were no significant differences in other measures of blood pressure, including office systolic or diastolic blood pressure,” said David E. Kandzari,...
“We saw a modest but...
04/09/2024
Cath Lab Digest
aortic stenosis
ACC.24: DEDICATE-DZHK6 Trial Finds TAVR Non-Inferior to SAVR for Low-Risk Patients
04/09/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
“We can now provide strong data that in this low-risk patient population, you could very safely offer TAVR vs. SAVR,” said Moritz Seiffert, MD, professor of cardiology at BG University Hospital Bergmannsheil, Ruhr University Bochum in Bochum,...
“We can now provide strong data that in this low-risk patient population, you could very safely offer TAVR vs. SAVR,” said Moritz Seiffert, MD, professor of cardiology at BG University Hospital Bergmannsheil, Ruhr University Bochum in Bochum,...
“We can now provide strong data...
04/09/2024
Cath Lab Digest

Advertisement

angina
ACC.24: ORBITA-COSMIC - Coronary Sinus Reducer Relieves Angina, But How It Works Remains Unclear
04/09/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
The trial focused on patients with angina due to plaque buildup in the coronary arteries that is not adequately controlled with available treatments. The CSR is an hourglass-shaped stent designed to narrow the vein that collects blood from...
The trial focused on patients with angina due to plaque buildup in the coronary arteries that is not adequately controlled with available treatments. The CSR is an hourglass-shaped stent designed to narrow the vein that collects blood from...
The trial focused on patients...
04/09/2024
Cath Lab Digest
refractory angina
ACC.24: Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study
04/09/2024

Shockwave Medical News

Shockwave Medical News
REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
REDUCER-I is a post-market, multi-center, observational study designed to collect long-term outcomes on Shockwave Reducer in a large, ‘real-world’ population of 400 patients.
REDUCER-I is a post-market,...
04/09/2024
Cath Lab Digest
nonvalvular atrial fibrillation
ACC.24: PIONEER AF-PCI Clinical Trial Finds XARELTO (rivaroxaban) Reduces Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
04/09/2024

Johnson & Johnson News

Johnson & Johnson News
A new analysis of data from the PIONEER AF-PCI clinical trial demonstrates that XARELTO® (rivaroxaban) is associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of...
A new analysis of data from the PIONEER AF-PCI clinical trial demonstrates that XARELTO® (rivaroxaban) is associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of...
A new analysis of data from the...
04/09/2024
Cath Lab Digest

Advertisement

aorto-iliac occlusive disease
Getinge iCast Covered Stent System Considered Medically Necessary for Treatment of Iliac Arterial Occlusive Disease
04/09/2024

Getinge News

Getinge News
Getinge announced Aetna, a leading health insurance benefits company in the United States, issued a Clinical Policy Bulletin (CPB) addressing peripheral vascular stents. Aetna issued a revised CPB stating that the iCast covered stent...
Getinge announced Aetna, a leading health insurance benefits company in the United States, issued a Clinical Policy Bulletin (CPB) addressing peripheral vascular stents. Aetna issued a revised CPB stating that the iCast covered stent...
Getinge announced Aetna, a...
04/09/2024
Cath Lab Digest
Endovascular Imaging
ACC.24: IVUS-DCB - Intravascular Ultrasound Outperforms Angiography for PAD Treatment
04/08/2024

American College of Cardiology Scientific Sessions News

American College of Cardiology Scient...
“IVUS is more accurate than angiography in measuring vessel dimensions. It facilitates achieving sufficient vessel lumen diameters and aids in evaluating the response of the target lesion to treatment,” said Young-Guk Ko, MD, the study’s lead...
“IVUS is more accurate than angiography in measuring vessel dimensions. It facilitates achieving sufficient vessel lumen diameters and aids in evaluating the response of the target lesion to treatment,” said Young-Guk Ko, MD, the study’s lead...
“IVUS is more accurate than...
04/08/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

News

DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest
acute mI
CLEAR SYNERGY (OASIS 9) Trial @TCT: Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes
10/30/2024
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication...
10/30/2024
Cath Lab Digest
Intravascular Lithotripsy
Data From Elixir’s PINNACLE I Trial for Calcium Fragmentation in Calcified Coronary Artery Lesions Presented at TCT
10/30/2024
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging...
10/30/2024
Cath Lab Digest
Tricuspid Valve Treatment
TCT: TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
10/30/2024
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized...
10/30/2024
Cath Lab Digest
Post MI
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
10/30/2024
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in...
10/30/2024
Cath Lab Digest
Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest
Large Bore Closure
TCT: Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal Large Hole Closure Device
10/29/2024
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure...
10/29/2024
Cath Lab Digest

Advertisement

Advertisement

TAVR
TAVR UNLOAD @TCT: Transcatheter Aortic Valve Replacement in Patients with Systolic Heart Failure and Moderate Aortic Stenosis Shows Limited Benefits
10/30/2024
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD...
10/30/2024
Cath Lab Digest
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest
acute mI
CLEAR SYNERGY (OASIS 9) Trial @TCT: Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes
10/30/2024
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication...
10/30/2024
Cath Lab Digest
Intravascular Lithotripsy
Data From Elixir’s PINNACLE I Trial for Calcium Fragmentation in Calcified Coronary Artery Lesions Presented at TCT
10/30/2024
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging...
10/30/2024
Cath Lab Digest
Tricuspid Valve Treatment
TCT: TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
10/30/2024
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized...
10/30/2024
Cath Lab Digest
Post MI
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
10/30/2024
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in...
10/30/2024
Cath Lab Digest
Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use